All lobbying filings

ACADIA PHARMACEUTICALS

Lobbying for ACADIA PHARMACEUTICALS

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $440,000.00 expenses · posted Apr 18, 2025

Official filing document

Bills named in this filing 4

HR 946
ORPHAN Cures Act
HR 1262
Mikaela Naylon Give Kids a Chance Act
HR 1414
Cameron’s Law
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 3

Health Issues

Implementation of the Inflation Reduction Act of 2022; Orphan Cures Act (HR 946); National Plan to End Parkinsons Act (Public Law 118-66, 118th Congress); Give Kids A Chance (HR1262); Cameron's Law (HR1414).

Medicare/Medicaid

Implementation of the Inflation Reduction Act of 2022; Issues related to protecting patient access to medicines in Medicare; Issues related to access to medicines for Parkinson's disease patients; Issues related to Antipsychotic use in Medicare; Orphan Cures Act (HR 946); National Plan to End Parkinsons Act (Public Law 118-66, 118th Congress); EPIC Act (HR 1492).

Taxation/Internal Revenue Code

Cameron's Law (HR 14114)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.